AU · rank #18 · 2026-09-10
CORT
NASDAQ · $12.51B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 0.714 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$1.20 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 2 |
| Insider signal (90d) $0 across 0 unique buyers. | -0.172 |
| Analyst upside Consensus target $141.00 | +21.9% |
| Momentum acceleration 3-month minus 12-month momentum. | +24.16% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.50 |
| Gross margin TTM | +98.3% |
| 52w high | $126.38 |
| Market cap (USD) | $12.51B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Corcept Therapeutics is a biopharmaceutical company specializing in cortisol receptor antagonists, deriving the vast majority of its revenue from treating Cushing’s syndrome with its Korlym franchise and newly launched Lifyorli [1, 2].
Rationale
A massive 535% Q2 earnings surprise, 100% upward revision agreement, and raised FY26 guidance strongly validate the analyst upside signal and reflect accelerating fundamental momentum [1].
Material risks
- 1Extreme revenue concentration in Korlym and its authorized generic exposes the company to severe top-line erosion from generic competition or reimbursement changes [1, 2].
- 2Execution and commercialization risks surrounding the launch of Lifyorli could cause growth to stall if uptake fails to meet raised full-year expectations [1].
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.